Fate of iron stores in thalassaemia after bone-marrow transplantation. 1993

G Lucarelli, and E Angelucci, and C Giardini, and D Baronciani, and M Galimberti, and P Polchi, and M Bartolucci, and P Muretto, and F Albertini
Divisione Ematologica, Ospedale di Pesaro, Italia.

After successful bone-marrow transplantation (BMT) in thalassaemia, the individual acquires the pattern of globin synthesis of the donor. We call such an individual "ex-thalassaemic after BMT", a term that underscores the cure of the genetic defect but maintenance of residual signs of organ damage due to iron overload and dysfunction acquired during the pretransplant years. We have analysed the extent and fate of tissue iron overload in 151 ex-thalassaemic patients after BMT, according to the risk factors of hepatomegaly, hepatic portal fibrosis, and inadequate chelation therapy. Serum ferritin concentrations decreased and unbound iron binding capacity (UIBC) increased slowly during the years after the transplant. When analysed according to risk group (assigned at the time of the transplant), ferritin and UIBC returned within the normal ranges in only the low-risk group (without hepatomegaly or portal fibrosis, and with adequate chelation pre-BMT). Ferritin and UIBC were still abnormal 7 years after the transplant in the moderate-risk group (those with one or two risk factors) and highly abnormal in the high-risk group (all three risk factors) indicating persistence of, respectively, moderate and severe iron overload at the time of transplant. In ex-thalassaemic patients who were studied before and yearly after the transplant the extent of haemosiderosis, as judged by staining of liver biopsy samples, decreased during the years after transplant. The degree of iron deposition and rate of post-BMT linear growth seem to influence rate of post-BMT decrease in tissue iron overload in different risk groups at the time of BMT.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007501 Iron A metallic element with atomic symbol Fe, atomic number 26, and atomic weight 55.85. It is an essential constituent of HEMOGLOBINS; CYTOCHROMES; and IRON-BINDING PROTEINS. It plays a role in cellular redox reactions and in the transport of OXYGEN. Iron-56,Iron 56
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D011184 Postoperative Period The period following a surgical operation. Period, Postoperative,Periods, Postoperative,Postoperative Periods
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005293 Ferritins Iron-containing proteins that are widely distributed in animals, plants, and microorganisms. Their major function is to store IRON in a nontoxic bioavailable form. Each ferritin molecule consists of ferric iron in a hollow protein shell (APOFERRITINS) made of 24 subunits of various sequences depending on the species and tissue types. Basic Isoferritin,Ferritin,Isoferritin,Isoferritin, Basic
D006486 Hemosiderosis Conditions in which there is a generalized increase in the iron stores of body tissues, particularly of liver and the MONONUCLEAR PHAGOCYTE SYSTEM, without demonstrable tissue damage. The name refers to the presence of stainable iron in the tissue in the form of hemosiderin. Hemosideroses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

G Lucarelli, and E Angelucci, and C Giardini, and D Baronciani, and M Galimberti, and P Polchi, and M Bartolucci, and P Muretto, and F Albertini
March 2000, Bone marrow transplantation,
G Lucarelli, and E Angelucci, and C Giardini, and D Baronciani, and M Galimberti, and P Polchi, and M Bartolucci, and P Muretto, and F Albertini
January 1989, Progress in clinical and biological research,
G Lucarelli, and E Angelucci, and C Giardini, and D Baronciani, and M Galimberti, and P Polchi, and M Bartolucci, and P Muretto, and F Albertini
May 1986, Bone marrow transplantation,
G Lucarelli, and E Angelucci, and C Giardini, and D Baronciani, and M Galimberti, and P Polchi, and M Bartolucci, and P Muretto, and F Albertini
July 1996, Bone marrow transplantation,
G Lucarelli, and E Angelucci, and C Giardini, and D Baronciani, and M Galimberti, and P Polchi, and M Bartolucci, and P Muretto, and F Albertini
March 1986, The Medical journal of Australia,
G Lucarelli, and E Angelucci, and C Giardini, and D Baronciani, and M Galimberti, and P Polchi, and M Bartolucci, and P Muretto, and F Albertini
January 1997, Journal of internal medicine. Supplement,
G Lucarelli, and E Angelucci, and C Giardini, and D Baronciani, and M Galimberti, and P Polchi, and M Bartolucci, and P Muretto, and F Albertini
November 1991, Archives of disease in childhood,
G Lucarelli, and E Angelucci, and C Giardini, and D Baronciani, and M Galimberti, and P Polchi, and M Bartolucci, and P Muretto, and F Albertini
April 1991, Archives of disease in childhood,
G Lucarelli, and E Angelucci, and C Giardini, and D Baronciani, and M Galimberti, and P Polchi, and M Bartolucci, and P Muretto, and F Albertini
July 1992, Journal of clinical pathology,
G Lucarelli, and E Angelucci, and C Giardini, and D Baronciani, and M Galimberti, and P Polchi, and M Bartolucci, and P Muretto, and F Albertini
July 1985, Lancet (London, England),
Copied contents to your clipboard!